Related Experiment Videos
Mode of death from congestive heart failure: implications for clinical management
Mary Clare Derfler1, Mark Jacob, Robert E Wolf
1Division of Cardiology, Department of Medicine, Saint Louis University School of Medicine, MO 63110, USA.
Insights
Understanding end-stage heart failure deaths is crucial. This study identified predictors for metabolic and progressive heart failure deaths, aiding in better patient care strategies.
Area of Science:
- Cardiology
- Geriatrics
- Palliative Care
Background:
- End-stage heart failure patient care is understudied.
- Best care practices for these patients remain unclear.
Purpose of the Study:
- To characterize patients dying from heart failure.
- To identify clinical predictors of metabolic and progressive heart failure deaths.
Main Methods:
- Retrospective chart review of a university-based heart failure disease management program.
- Utilized new definitions for mode of death due to heart failure.
Main Results:
- Over a 60-month period, 17.6% of deaths were metabolic and 21.3% were progressive.
- Continuous inotropic support and pre-existing renal failure predicted non-sudden cardiac death.
- Significant resource utilization observed, with few patients in hospice.
Conclusions:
- Prospective identification of patients at risk for metabolic and progressive heart failure death is feasible.
- The incidence of these deaths is expected to rise with implantable cardioverter-defibrillators.
- Intervention studies focusing on symptom control are recommended for at-risk patients.
Abstract:
The care of the end-stage patient has not been extensively studied, and little is known about best care practices. Therefore, using new definitions for mode of death due to heart failure, we performed a retrospective chart review of records from a university-based heart failure disease management program to characterize the population of patients dying from heart failure and to define clinical predictors that identify patients who will likely die of metabolic and/or progressive causes. Of 74 deaths recorded over a 60-month period, 17.6% and 21.3% were deemed to be metabolic or progressive, respectively. Utilization of resources was considerable, and only a small number of patients died while in hospice. Patients who required continuous inotropic support and those with preexisting renal failure were at highest risk for non-sudden cardiac death. We conclude that prospective identification of patients at risk for metabolic and progressive heart failure death is possible. The numbers of these patients is likely to increase in an era of implantable cardioverter-defibrillators. Intervention studies designed to evaluate and improve strategies that emphasize symptom control should target this group.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure III: Clinical Manifestations
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VII: Nursing Interventions
Heart Failure VI: Adjunct Therapies